

Redefining long-term outcomes in the era of personalised medicine: maintenance treatment in newly diagnosed ovarian cancer

This symposium is organised and sponsored by AstraZeneca



Agenda

On demand from Tuesday, 22 September 2020, 09:00 CEST

5 min **Chair's welcome and introductions**
Ana Oaknin (Spain)



15 min **Pioneering with PARP inhibition:
rationale for maintenance therapy
in newly diagnosed ovarian cancer**
Thomas Herzog (USA)



20 min **Broadening horizons: new data and
combinations with PARP inhibitors**
Isabelle Ray-Coquard (France)



20 min **Optimising clinical outcomes: the case for
personalised medicine in ovarian cancer**
Ignace Vergote (Belgium)



25 min **Panel discussion**
All

5 min **Summary and meeting close**
Ana Oaknin (Spain)

Live on Monday, 28 September 2020, 15:30 CEST

60 min **Audience Q&A**
All